Amino acid substitutions in the S region of hepatitis B virus in sera from patients with acute hepatitis

Hepatology Research

Volumn 37, Issue 9, 2007, Pages 731-739

  Aono, Junko ^a,b   Yotsuyanagi, Hiroshi ^a   Miyoshi, Hideyuki ^a   Tsutsumi, Takeya ^a   Fujie, Hajime ^a   Shintani, Yoshizumi ^a   Moriya, Kyoji ^a   Okuse, Chiaki ^c   Suzuki, Michihiro ^c   Yasuda, Kiyomi ^d   Iino, Shiro ^d   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TEIKYO HEISEI UNIVERSITY   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Seizankai Kiyokawa Hospital   (Japan)

Author keywords

Genotype; Hepatitis B virus; Major hydrophilic region; Vaccine

Indexed keywords

AMINO ACID; BIMMUGEN; HEPTAVAX; MEINYU; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYDROPHILICITY; JAPAN; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; SEQUENCE ANALYSIS; SERODIAGNOSIS; STRAIN DIFFERENCE; VACCINATION; VIRUS ISOLATION; VIRUS TRANSMISSION;

EID: 34447329826     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00120.x     Document Type: Article

References (33)

1. Manno M, Camma C, Schepis F et al. Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756-63.
2. Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Liver 1989; 9: 235-41.
3. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-8.
4. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988; 8: 493-6.
5. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-9.
6. Ni YH, Chang MH, Huang LM et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135: 796-800.
7. Tanaka J, Kumagai J, Katayama K et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 34856 48 first-time blood donors during 1995-2000. Intervirology 2004; 47: 32-40.
8. Kobayashi M, Suzuki F, Arase Y et al. Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. J Gastroenterol 2004; 39: 844-50.
9. Yotsuyanagi H, Okuse C, Yasuda K et al. Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. J Med Virol 2005; 77: 39-46.
10. Suzuki Y, Kobayashi M, Ikeda K et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 2005; 76: 33-9.
11. Water JA, Kennedy M, Voet P et al. Loss of the common 'A' determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992; 90: 2543-7.
12. Heijtink RA, Schneeberger PM, Postma B, Crombach W. Anti-HBs levels after hepatitis B immunisation depend on test reagents: Routinely determined 10 and 100 IU/L seroprotection levels unreliable. Vaccine 2002; 20: 2899-905.
13. Hieu NT, Kim KH, Janowicz Z, Timmermans I. Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: An assessment at 2years. Vaccine 2002; 20: 1803-8.
14. Kamisango K, Kamogawa C, Sumi M et al. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J Clin Microbiol 1999; 37: 310-14.
15. Kato H, Orito E, Sugauchi F et al. Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. J Virol Methods 2003; 110: 29-35.
16. Koike K, Yoshida E, Katagiri K et al. Production of hepatitis B virus surface antigen particles by the human hepatoma cell line huGK-14 in a serum-free medium. Jpn J Cancer Res 1987; 78: 1341-6.
17. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307: 178-80.
18. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298: 347-50.
19. Sugita S, Yoshioka Y, Itamura S et al. Molecular evolution of hemagglutinin genes of H1N1 swine and human influenza A viruses. J Mol Evol 1991; 32: 16-23.
20. Kyte J, Doolittle F. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982; 157: 105-32.
21. Garnier J, Osguthorpe DJ, Robson B. Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J Mol Biol 1978; 120: 97-120.
22. Chou PY, Fasman GD. Conformational parameters for amino acids in helical, β-sheet, and random coil regions calculated from proteins. Biochemistry 1974; 13: 211-12.
23. Ni YH, Chang MH, Huang LM et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135: 796-80.
24. Hou J, Wang Z, Cheng J et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 2001; 34: 1027-34.
25. Ogata N, Cote PJ, Zanetti AR et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 1999; 30: 779-86.
26. Paulij WP, de Wit PL, Sunnen CM et al. Localization of a unique hepatitis B virus epitope sheds new light on the structure of hepatitis B virus surface antigen. J Gen Virol 1999; 80: 2121-6.
27. Carman WF, Zanetti AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-9.
28. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345: 1406-7.
29. Lee PI, Chang LY, Lee CY, Huang LM, Chang MH. Detection of hepatitis B surface gene mutation in carrier children with or without immunoprophylaxis at birth. J Infect Dis 1997; 176: 427-30.
30. Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 254-63.
31. Shields PL, Owsianka A, Carman WF et al. Selection of hepatitis B surface 'escape' mutants during passive immune prophylaxis following liver transplantation: Potential impact of genetic changes on polymerase protein function. Gut 1999; 45: 306-9.
32. Yamamoto K, Horikita M, Tsuda F et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994; 68: 2671-6.
33. Kato J, Hasegawa K, Torii N, Yamauchi K, Hayashi N. A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B. Hepatology 1996; 23: 389-95.